Vertex Pharmaceuticals (VRTX) Assets (2009 - 2026)

Vertex Pharmaceuticals has reported Assets for 18 years, with the latest figure at $27.4 billion in Q2 2026.

• On a quarterly basis, Assets rose 14.09% year-over-year to $27.4 billion in Q2 2026; TTM through Jun 2026 was $27.4 billion, a 14.09% increase from a year earlier, with the FY2025 full-year figure at $25.6 billion, up 13.8% from the prior year.
• Assets was $27.4 billion for Q2 2026 at Vertex Pharmaceuticals, up from $26.5 billion in the prior quarter.
• The five-year high for Assets was $27.4 billion in Q2 2026, with the low at $14.3 billion in Q1 2022.
• Average Assets over 5 years is $21.6 billion, with a median of $22.4 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Assets soared 35.13% in 2022, then decreased 4.34% in 2025.
• Over 5 years, Assets stood at $18.2 billion in 2022, then grew by 25.23% to $22.7 billion in 2023, then dropped by 0.87% to $22.5 billion in 2024, then climbed by 13.8% to $25.6 billion in 2025, then rose by 6.94% to $27.4 billion in 2026.
• The last three Assets figures came in at $27.4 billion (Q2 2026), $26.5 billion (Q1 2026), and $25.6 billion (Q4 2025), per Business Quant data.